Jagsonpal Pharmaceuticals Ltd.

236.62

1.6 (0.7%)stock indicator image for upward trend

JAGSNPHARM Share Price
As on July 3, 2026
SectorHealthcare
IndustryPharmaceuticals & Biotechnology
Basic IndustryPharmaceuticals
Market Cap1,558 Cr
P/E Ratio28.38
Dividend Yield0.53 %
Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

This image for unlock stock of the monthUnlock Stock of the Month

T&C*

Company Information


Market Insights
Open236
High240
NSE SymbolJAGSNPHARM
Close236.62
Low230.26
BSE Symbol507789
Previous Years High/Low
1 Year High301.65
3 Year High328.04
5 Year High328.04
1 Year Low155
3 Year Low109.44
5 Year Low49.2

Technicals


IndicatorsValueSignal
5-DMA235.61Bullish
10-DMA229.84Bullish
20-DMA218.47Bullish
50-DMA211.27Bullish
100-DMA196.02Bullish
200-DMA201.33Bullish

Historical Performance


1 Year
3%
3 Years
58.9%
5 Years
288.8%
10 Years
1298.5%

Shareholding Pattern


%

Values Analysis


Loading chart...

Profit & Loss

Below figures are in Rs. Crores


Compounded Sales Growth
10 Years:N/A
5 Years:N/A
3 Years:N/A
TTM:N/A
Compounded Profit Growth
10 Years:N/A
5 Years:N/A
3 Years:N/A
TTM:N/A
Stock Price CAGR
10 Years:30.5
5 Years:31.8
3 Years:17.3
TTM:2.4
Return on Equity
10 Years:N/A
5 Years:N/A
3 Years:N/A
last year:N/A

Quarterly Results

Below figures are in Rs. Crores


ParticularsSep-2024Dec-2024Mar-2025Jul-2025Sep-2025
Sales1,70,7541,35,9361,28,5521,22,1891,05,161
Expenses63,04256,55752,45745,45934,856
Operating Profit1,07,71279,37976,09676,73070,304
OPM %63%58%59%63%67%
Other Income33,91231,75927,33324,87918,947
Interest77,78058,58459,24862,13753,713
Depreciation2,3451,6811,3851,2771,221
Profit Before Tax61,49850,87342,79638,19534,318
Tax %25%25%26%29%35%
Net Profit46,14938,15131,85727,29622,446
EPS in Rs8369585042

Balance Sheet

Below figures are in Rs. Crores


0%
Positive
(80 to 100)
Neutral
(60 to 79)
Negative
(0 to 59)
  • The stock has a high PE of 28.38, indicating expensive valuation or elevated growth expectations.
  • Over the last three years, the stock delivered a strong 3-year price CAGR of 17.3%, indicating sustained price appreciation.
  • The stock carries a low beta of 0.5, suggesting lower volatility than the broader market.
  • In the last financial year, the company reported an EBITDA of ₹593 million, reflecting positive operating performance.
  • In the previous financial year, the company generated revenue of ₹2687 million, suggesting a mid-sized operation.

Investment Calculator


Investment Amount: ₹ 1000000
Current Value: ₹ 1025794.4
No. of Shares: 4335 (Approx)
Performance:2.6%
P/L: ₹25794.4
NIFTY Performance: -4.7%
1 day Top Gainers
SymbolChange%
SUMICHEM502.3(14%)
ZENSARTECH516.1(10%)
AEGISVOPAK257.43(10%)
ECLERX1488.8(7%)
KAYNES3333.8(6%)
1 Day Top Losers
SymbolChange%
GVT&D4401.5(-9%)
POWERINDIA31040(-8%)
ENRIN3281.5(-8%)
CGPOWER892.55(-7%)
UNIONBANK163.09(-7%)
THERMAX4607.5(-6%)
APARINDS14174(-6%)
TARIL336.75(-6%)

Top Performing Stocks from the same sector


Beta Drugs Ltd.

43.8%

2090.5

1 Month Performance

Bafna Pharmaceuticals Ltd.

41.8%

216.45

1 Month Performance

Ind-Swift Laboratories Ltd.

36.3%

214.16

1 Month Performance

Amanta Healthcare Ltd.

33.3%

163.09

1 Month Performance

Senores Pharmaceuticals Ltd.

32.2%

1381.9

1 Month Performance

Morepen Laboratories Ltd.

30.1%

59.07

1 Month Performance

Caplin Point Laboratories Ltd.

28.6%

2538.1

1 Month Performance

Panacea Biotec Ltd.

27.1%

551.2

1 Month Performance

Get Your Portfolio Reviewed

Stock of the Month
Stock of the Month